PURPOSE: Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active NTRK fusions have been remarkably effective. Herein, we analyze the prevalence of the full array of NTRK alterations-fusions, mutations, copy number alterations, and increased transcript expression-in diverse adult and pediatric tumor types to understand the landscape of NTRK aberrations in cancer. METHODS: We assessed 13,467 samples available from The Cancer Genome Atlas (adult tumors) and the St Jude PeCan database (pediatric tumors) for the prevalence of NTRK fusions, as well as associated genomic and transcriptomic co-aberrations in different tumor types. RESULTS: NTRK fusions were observed in 0.31% of adult tumors and in 0.34% of pediatric tumors. The most common gene partners were NTRK3 (0.16% of adult tumors) followed by NTRK1 (0.14% of pediatric tumors). NTRK fusions were found more commonly in pediatric melanoma (11.1% of samples), pediatric glioma (3.97%), and adult thyroid cancers (2.34%). Additional genomic and transcriptomic NTRK alterations- mutation, amplification, and mRNA overexpression-occurred in 14.2% of samples, whereas the frequency of alterations that implicated NTRK ligands and the NTRK co-receptor (p75NTR) ranged from 3.8% to 5.4%. Among 31 adult samples carrying NTRK fusions, co-alterations occurred often and usually involved the downstream phosphoinositide-3-kinase signaling pathway, cell-cycle machinery, other tyrosine-kinase receptors, and mitogen-activated protein kinase signals. CONCLUSION: Whereas NTRK fusions are exceedingly rare, other NTRK abnormalities affect 14% of patients with cancer. Affecting these alterations has not yet been achievable in cancer. Genomic co-alterations occur frequently with NTRK fusions, but it is not known if co-targeting them can attenuate primary or secondary resistance to NTRK inhibitors.
PURPOSE: Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active NTRK fusions have been remarkably effective. Herein, we analyze the prevalence of the full array of NTRK alterations-fusions, mutations, copy number alterations, and increased transcript expression-in diverse adult and pediatric tumor types to understand the landscape of NTRK aberrations in cancer. METHODS: We assessed 13,467 samples available from The Cancer Genome Atlas (adult tumors) and the St Jude PeCan database (pediatric tumors) for the prevalence of NTRK fusions, as well as associated genomic and transcriptomic co-aberrations in different tumor types. RESULTS: NTRK fusions were observed in 0.31% of adult tumors and in 0.34% of pediatric tumors. The most common gene partners were NTRK3 (0.16% of adult tumors) followed by NTRK1 (0.14% of pediatric tumors). NTRK fusions were found more commonly in pediatric melanoma (11.1% of samples), pediatric glioma (3.97%), and adult thyroid cancers (2.34%). Additional genomic and transcriptomic NTRK alterations- mutation, amplification, and mRNA overexpression-occurred in 14.2% of samples, whereas the frequency of alterations that implicated NTRK ligands and the NTRK co-receptor (p75NTR) ranged from 3.8% to 5.4%. Among 31 adult samples carrying NTRK fusions, co-alterations occurred often and usually involved the downstream phosphoinositide-3-kinase signaling pathway, cell-cycle machinery, other tyrosine-kinase receptors, and mitogen-activated protein kinase signals. CONCLUSION: Whereas NTRK fusions are exceedingly rare, other NTRK abnormalities affect 14% of patients with cancer. Affecting these alterations has not yet been achievable in cancer. Genomic co-alterations occur frequently with NTRK fusions, but it is not known if co-targeting them can attenuate primary or secondary resistance to NTRK inhibitors.
Authors: Edgar R Wood; Lee Kuyper; Kimberly G Petrov; Robert N Hunter; Philip A Harris; Karen Lackey Journal: Bioorg Med Chem Lett Date: 2004-02-23 Impact factor: 2.823
Authors: Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen Journal: Cancer Cell Date: 2002-11 Impact factor: 31.743
Authors: Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Matthew Clarke; Alan Mackay; Britta Ismer; Jessica C Pickles; Ruth G Tatevossian; Scott Newman; Tejus A Bale; Iris Stoler; Elisa Izquierdo; Sara Temelso; Diana M Carvalho; Valeria Molinari; Anna Burford; Louise Howell; Alex Virasami; Amy R Fairchild; Aimee Avery; Jane Chalker; Mark Kristiansen; Kelly Haupfear; James D Dalton; Wilda Orisme; Ji Wen; Michael Hubank; Kathreena M Kurian; Catherine Rowe; Mellissa Maybury; Stephen Crosier; Jeffrey Knipstein; Ulrich Schüller; Uwe Kordes; David E Kram; Matija Snuderl; Leslie Bridges; Andrew J Martin; Lawrence J Doey; Safa Al-Sarraj; Christopher Chandler; Bassel Zebian; Claire Cairns; Rachael Natrajan; Jessica K R Boult; Simon P Robinson; Martin Sill; Ira J Dunkel; Stephen W Gilheeney; Marc K Rosenblum; Debbie Hughes; Paula Z Proszek; Tobey J Macdonald; Matthias Preusser; Christine Haberler; Irene Slavc; Roger Packer; Ho-Keung Ng; Shani Caspi; Mara Popović; Barbara Faganel Kotnik; Matthew D Wood; Lissa Baird; Monika Ashok Davare; David A Solomon; Thale Kristin Olsen; Petter Brandal; Michael Farrell; Jane B Cryan; Michael Capra; Michael Karremann; Jens Schittenhelm; Martin U Schuhmann; Martin Ebinger; Winand N M Dinjens; Kornelius Kerl; Simone Hettmer; Torsten Pietsch; Felipe Andreiuolo; Pablo Hernáiz Driever; Andrey Korshunov; Lotte Hiddingh; Barbara C Worst; Dominik Sturm; Marc Zuckermann; Olaf Witt; Tabitha Bloom; Clare Mitchell; Evelina Miele; Giovanna Stefania Colafati; Francesca Diomedi-Camassei; Simon Bailey; Andrew S Moore; Timothy E G Hassall; Stephen P Lowis; Maria Tsoli; Mark J Cowley; David S Ziegler; Matthias A Karajannis; Kristian Aquilina; Darren R Hargrave; Fernando Carceller; Lynley V Marshall; Andreas von Deimling; Christof M Kramm; Stefan M Pfister; Felix Sahm; Suzanne J Baker; Angela Mastronuzzi; Andrea Carai; Maria Vinci; David Capper; Sergey Popov; David W Ellison; Thomas S Jacques; David T W Jones; Chris Jones Journal: Cancer Discov Date: 2020-04-01 Impact factor: 39.397